

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/019437

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ A61K31/365, A61P35/00, A23L1/30//C07D307/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ A61K31/365, A61P35/00, A23L1/30//C07D307/32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS (STN), MEDLINE (STN), REGISTRY (STN), JOIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 11-221048 A (Archer Daniels Midland Co.), 17 August, 1999 (17.08.99), Particularly, Claims 18, 34, 61, 62 & EP 906761 A2 07 April, 1999 (07.04.99)	1-5
X	JP 2003-63971 A (Tama Biochemical Co., Ltd.), 05 March, 2003 (05.03.03), Particularly, Par. Nos. [0005], [0016], [0019] (Family: none)	1-5

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:
 "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search
17 January, 2005 (17.01.05)

Date of mailing of the international search report
08 February, 2005 (08.02.05)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/019437

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 2002-541158 A (HORMOS NUTRACEUTICAL OY LTD.), 03 December, 2002 (03.12.02), Particularly, Claims 1, 10; Par. No. [0009] & EP 1165537 A1 02 January, 2002 (02.01.02) & US 6451849 A 17 September, 2002 (17.09.02)	1-5
X	JP 1-228928 A (Tsumura & Co.), 12 September, 1989 (12.09.89), Particularly, Claim 7; example 9 (Family: none)	1-5
X	US 2003-0118676 A (COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH), 26 June, 2003 (26.06.03), Particularly, table 3 & WO 03/47608 A1 12 June, 2003 (12.06.03)	1-5
X	THOMPSON L.U., Role of lignans in carcinogenesis, Phytochemicals in Human Health Protection, Nutrition, and Plant Defense, 1999, pages 51 to 65	1-5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/019437

<Subject of search>

Although the statement in the description is examined, it appears unclear to what extent of structures are included in the term "a plant lignanprecursor", which makes the scopes of the compound and drug according to the present invention unclear.

In this international search report, therefore, prior art documents were examined based on the compounds specifically presented in the description.